Weight Gain: What Could Be Causing It?

How Much Weight Gain Is Actually Abnormal?

Normal body weight fluctuates by 1 to 2 kg day-to-day due to fluid shifts, food volume, and hormonal cycles. Clinically significant gain is defined as an unintentional increase of 5% or more of baseline body weight over 6 to 12 months, or any gain exceeding 2 kg within a single week.

The 5% Rule in Practice

The 5% threshold matters because it predicts metabolic harm. A 2013 analysis in Diabetes Care showed that a 5% to 10% weight reduction in people with prediabetes reduced progression to type 2 diabetes by roughly 58% over 3 years in the Diabetes Prevention Program. The corollary: gaining that same proportion carries proportionate metabolic risk. Clinicians use 5% as the trigger for structured evaluation rather than lifestyle counseling alone.

Rapid Gain vs. Gradual Gain

The pace of gain directs the workup. Rapid gain, defined here as more than 0.5 kg per week sustained over 4 weeks, points toward fluid retention, medication introduction, or an endocrine crisis. Gradual gain over years more often reflects cumulative caloric surplus, progressive insulin resistance, or slow-onset thyroid disease. Separating these two patterns at the first visit saves significant diagnostic time.

The Most Common Causes of Unexplained Weight Gain

Hypothyroidism

Thyroid hormone governs basal metabolic rate. When thyroid-stimulating hormone (TSH) rises above 4.5 mIU/L, indicating under-active thyroid function, the body burns roughly 200 to 500 fewer calories per day at rest. The American Thyroid Association estimates that overt hypothyroidism affects 0.3% of the general population, while subclinical hypothyroidism (TSH 4.5 to 10 mIU/L with normal free T4) affects an additional 4.3%.

Weight gain from hypothyroidism averages 2 to 5 kg and is partly water, partly true fat mass. Levothyroxine titrated to a TSH of 0.5 to 2.5 mIU/L typically reverses 60 to 80% of the gained weight within 6 months, though full reversal is not guaranteed.

Insulin Resistance and Type 2 Diabetes

Insulin is a storage hormone. Elevated fasting insulin, as seen in metabolic syndrome and early type 2 diabetes, directs excess glucose into adipose tissue. A 2021 systematic review in JAMA found that approximately 38% of U.S. Adults meet criteria for prediabetes, most of whom are asymptomatic.

Fasting glucose above 100 mg/dL or an HbA1c of 5.7% to 6.4% confirms prediabetes and should trigger both lifestyle intervention and, in many patients, metformin 500 to 1,000 mg twice daily per ADA Standards of Care 2024.

Cushing Syndrome

Cortisol excess, whether from exogenous corticosteroids or endogenous overproduction, redistributes fat to the abdomen, face, and upper back. The classic presentation includes central obesity, a dorsocervical fat pad ("buffalo hump"), purple striae wider than 1 cm, and proximal muscle weakness.

A 2015 review in the New England Journal of Medicine notes that endogenous Cushing syndrome is rare, occurring in 10 to 15 per million people annually, but iatrogenic Cushing from prescribed steroids is far more common. Any patient on prednisone above 7.5 mg/day for more than 4 weeks warrants monitoring.

Polycystic Ovary Syndrome

PCOS affects 6% to 10% of women of reproductive age and is the leading cause of unexplained weight gain and menstrual irregularity in that group, per Endocrine Society Clinical Practice Guidelines (2018). Hyperinsulinemia drives androgen excess, which in turn promotes visceral fat accumulation.

The Rotterdam criteria require two of three features: oligo-ovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound.

Medications That Cause Weight Gain

This category is underdiagnosed. Physicians infrequently list weight gain as a side effect when prescribing, yet medication-induced gain may account for up to 10% to 15% of obesity cases seen in primary care.

Antidepressants and Antipsychotics

Tricyclic antidepressants (amitriptyline, nortriptyline) and atypical antipsychotics (olanzapine, quetiapine, clozapine) are among the highest-risk agents. A 2017 meta-analysis in The Lancet Psychiatry covering 81 trials and more than 25,000 patients found that olanzapine produced a mean weight gain of 3.99 kg at 10 weeks compared with placebo.

SSRIs, particularly paroxetine and mirtazapine, also carry meaningful risk. Fluoxetine and sertraline are relatively weight-neutral in the first 6 months but may produce gain with longer-term use.

Corticosteroids

Prednisone, dexamethasone, and hydrocortisone increase appetite, drive fluid retention, and cause fat redistribution. A 2018 study in Obesity Reviews found that patients on long-term glucocorticoid therapy gained an average of 4 to 8 kg over 12 months. Dose reduction to the minimum effective level is the primary intervention.

Insulin and Sulfonylureas

Exogenous insulin and sulfonylureas (glipizide, glyburide) promote weight gain through increased glucose uptake into fat cells and hypoglycemia-driven compensatory eating. The UKPDS 34 trial showed that patients randomized to insulin gained an average of 4 kg more than metformin-treated patients over 10 years. Switching to weight-neutral agents (metformin, SGLT-2 inhibitors, GLP-1 receptor agonists) is a guideline-supported option.

Beta-Blockers and Certain Antihistamines

Older beta-blockers (atenolol, metoprolol) reduce metabolic rate and blunt exercise capacity, producing average gains of 1.2 to 2.5 kg. Sedating antihistamines (diphenhydramine, cetirizine) stimulate appetite through H1-receptor blockade in the hypothalamus. These gains are smaller but clinically relevant when added to other contributors.

Hormonal and Reproductive Causes

Menopause

Estrogen withdrawal shifts fat distribution from subcutaneous to visceral depots. The SWAN (Study of Women's Health Across the Nation) cohort found that women gained an average of 1.5 kg per year during the 3-year menopausal transition, independent of changes in diet or activity, per a 2019 analysis in Menopause.

Menopausal hormone therapy does not reverse this gain on average, but evidence from the Women's Health Initiative showed that combined estrogen-progestogen reduced abdominal fat accumulation compared with placebo. The Menopause Society 2023 position statement supports hormone therapy for appropriate candidates within 10 years of menopause onset or before age 60.

Hypogonadism in Men

Testosterone below 300 ng/dL (the FDA-recognized threshold for hypogonadism) reduces lean muscle mass and increases adiposity, particularly visceral fat. A 2013 randomized trial in the New England Journal of Medicine found that testosterone therapy in men with confirmed hypogonadism increased lean mass by 1.9 kg and reduced fat mass by 1.4 kg over 12 months.

Testosterone replacement therapy is FDA-approved for confirmed hypogonadism and requires verification of low morning testosterone on at least two occasions before initiation.

Pregnancy and Postpartum

Gestational weight gain is physiologically normal. The National Academies of Sciences guidelines recommend 11.5 to 16 kg total gain for women with a pre-pregnancy BMI of 18.5 to 24.9. Postpartum retention of more than 5 kg at 12 months postpartum is associated with a 4-fold increased risk of obesity at 10-year follow-up.

Lifestyle and Behavioral Causes

Caloric Surplus and Ultra-Processed Foods

The arithmetic of weight gain is straightforward: sustained energy intake above expenditure stores fat. What varies is why that surplus occurs. A 2019 randomized controlled trial in Cell Metabolism by Hall et al. (N=20) showed that participants assigned to an ultra-processed diet consumed 508 kcal/day more and gained 0.9 kg over 2 weeks compared with an unprocessed diet, despite being offered equivalent caloric availability. Palatability and food texture, not just caloric density, drive overconsumption.

Sleep Deprivation

Short sleep duration (under 7 hours per night) raises ghrelin, suppresses leptin, and increases cortisol. A meta-analysis of 30 prospective studies in Sleep Medicine Reviews found that short sleepers had 55% higher odds of obesity compared with adequate sleepers. Every hour of additional sleep deficit per night corresponded to approximately 0.35 kg higher body weight.

The CDC recommends 7 or more hours per night for adults. Treating obstructive sleep apnea, when present, does not reliably produce weight loss but does reduce cardiovascular risk and may improve adherence to other interventions.

Stress and Hypothalamic-Pituitary-Adrenal Activation

Chronic psychological stress elevates cortisol via the hypothalamic-pituitary-adrenal axis. Elevated cortisol increases appetite for calorie-dense foods and preferentially deposits fat in visceral depots. A 2014 review in Obesity Reviews summarized 14 longitudinal studies and found that chronic work stress produced a relative risk of 1.3 for obesity onset over 5 years.

Rarer Causes Worth Ruling Out

Fluid Retention (Edema)

Weight from fluid is not the same as adipose gain, but patients often cannot distinguish them. Causes include heart failure, nephrotic syndrome, hepatic cirrhosis, chronic venous insufficiency, and low albumin states. The red-flag threshold here is 2 kg within one week, which mandates prompt evaluation including BNP, echocardiogram, urinalysis, and liver function tests.

Hypothalamic Obesity

Damage to the ventromedial hypothalamus from craniopharyngioma, traumatic brain injury, or pituitary surgery disrupts satiety signaling profoundly. Hypothalamic obesity is notoriously resistant to caloric restriction and often requires pharmacological management with agents such as dextroamphetamine or octreotide in specialist centers.

Genetic and Syndromic Obesity

Monogenic obesity, due to loss-of-function mutations in LEP, LEPR, MC4R, or PCSK1, typically presents in childhood with severe hyperphagia. Prader-Willi syndrome and Bardet-Biedl syndrome are the most common syndromic forms. Adults presenting with childhood-onset severe obesity and additional features (intellectual disability, hypogonadism, polydactyly) warrant genetic referral.

How Weight Gain Is Diagnosed

A structured workup prevents unnecessary testing while catching correctable causes. The following sequence is consistent with Endocrine Society Clinical Practice Guidelines on Obesity (2015).

First-Line Laboratory Panel

• TSH (screens for hypothyroidism and hyperthyroidism)
• Fasting glucose and HbA1c (screens for insulin resistance and diabetes)
• Fasting lipid panel (metabolic syndrome marker)
• Morning cortisol or 24-hour urine free cortisol (screens for Cushing)
• Total testosterone with SHBG in men (evaluates hypogonadism)
• LH, FSH, free testosterone, and DHEA-S in women with menstrual irregularity

Second-Line Testing

If first-line results are equivocal, add: free T4 and thyroid antibodies, low-dose (1 mg) overnight dexamethasone suppression test, fasting insulin, C-peptide, pelvic ultrasound in women, and a sleep study if snoring or witnessed apnea is reported.

Medication Review

Every medication, supplement, and herbal product taken in the past 12 months should be listed and cross-referenced against weight-gain liability. Substitutions exist for most drug classes: bupropion or escitalopram instead of paroxetine, SGLT-2 inhibitors instead of sulfonylureas, amlodipine instead of atenolol.

The HealthRX Weight Gain Differential Framework organizes these causes into four tiers based on prevalence and treatability:

Tier 1 (Common and Correctable): Hypothyroidism, insulin resistance, medication effects, sleep deficit, caloric surplus. Tier 2 (Common, Partial Response): PCOS, menopause, hypogonadism, chronic stress. Tier 3 (Less Common, Specialist Required): Cushing syndrome, hypothalamic obesity, heart failure, cirrhosis. Tier 4 (Rare, Genetic Referral): Monogenic obesity, Prader-Willi syndrome, Bardet-Biedl syndrome.

Starting at Tier 1 and working outward prevents over-testing while capturing the highest-yield diagnoses first.

Treatment Options for Weight Gain

Treatment follows the cause. Reversing a medication, treating hypothyroidism, or addressing sleep apnea may produce spontaneous normalization without dedicated weight-loss therapy.

Lifestyle Intervention as the Foundation

The Diabetes Prevention Program (N=3,234) demonstrated that an intensive lifestyle intervention targeting 7% weight loss through 150 minutes per week of moderate activity and dietary change reduced diabetes incidence by 58% over 2.8 years. This remains the most replicated weight-related intervention in medicine.

A 500 to 750 kcal/day dietary deficit, achieved through reduced portion size or elimination of ultra-processed foods, produces 0.5 to 0.75 kg of loss per week in adherent patients. The composition of the deficit (low-fat vs. Low-carbohydrate) matters less than the total reduction, as shown in the DIETFITS trial (N=609) in JAMA (2018).

Pharmacological Options

For patients with BMI ≥30, or ≥27 with a comorbidity, FDA-approved medications include:

• Semaglutide 2.4 mg (Wegovy): In STEP-1 (N=1,961), produced 14.9% mean weight loss at 68 weeks vs. 2.4% with placebo (P<0.001). New England Journal of Medicine, 2021.
• Tirzepatide 15 mg (Zepbound): In SURMOUNT-1 (N=2,539), produced 20.9% mean weight loss at 72 weeks vs. 3.1% with placebo (P<0.001). New England Journal of Medicine, 2022.
• Bupropion-naltrexone (Contrave): Produced 6.1% weight loss vs. 1.3% placebo in the COR-I trial (N=1,742). The Lancet, 2010.
• Phentermine-topiramate ER (Qsymia): Produced 10.9% weight loss vs. 1.6% placebo in EQUIP (N=1,267) at 56 weeks. Obesity, 2012.

As the Endocrine Society states in its 2015 Obesity Guidelines: "Pharmacotherapy is recommended as an adjunct to lifestyle therapy for patients with a BMI of 30 or higher or 27 or higher in the presence of at least one obesity-related comorbidity."

Bariatric Surgery

Roux-en-Y gastric bypass produces 25 to 35% total body weight loss at 2 years and achieves type 2 diabetes remission in 60 to 80% of patients, per a 2014 New England Journal of Medicine trial (N=150). Surgery is indicated for BMI ≥40, or ≥35 with significant comorbidity, in patients who have failed adequate lifestyle and pharmacological attempts.

When Should You Worry About Weight Gain?

See a clinician promptly if any of the following apply:

• Gain of more than 2 kg in one week (may signal cardiac or renal decompensation)
• Swelling in the legs, ankles, or abdomen alongside weight gain
• Shortness of breath that has worsened with the weight gain
• New striae wider than 1 cm (may indicate cortisol excess)
• Gain accompanied by hair loss, cold intolerance, constipation, and fatigue (hypothyroidism cluster)
• Childhood-onset severe obesity with additional developmental features

The American Heart Association notes that abdominal obesity, defined as waist circumference above 88 cm in women or 102 cm in men, independently predicts cardiovascular mortality regardless of total body weight, per AHA Scientific Statement (2021).